688136.SHG Shandong Kexing Bioproducts Co. Ltd. A
- Market cap
- CNY 3.14B
- P/E
- 42.0x
- P/B
- 1.66x
- ROE
- 14.6%
- Dividend yield
- 1.83%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688136.SHG undervalued?
Graham number688136.SHG trades 76.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Kexing Bioproducts Co. Ltd. A fundamental analysis
No fundamental analysis for Shandong Kexing Bioproducts Co. Ltd. A yet.
Shandong Kexing Bioproducts Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Kexing Bioproducts Co. Ltd. A
Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and …
Full company profileShandong Kexing Bioproducts Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Kexing Bioproducts Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 616M | 891M | 1.19B | 1.22B | 1.29B | 1.32B | 1.26B | 1.41B | 1.54B | 1.21B |
| Gross Profit | 486M | 722M | 970M | 975M | 1.02B | 991M | 889M | 963M | 1.54B | 657M |
| Operating Income | 89.3M | 121M | 189M | 160M | 98.0M | -139M | -256M | 63.2M | 172M | -134M |
| EBITDA | 89.7M | 144M | 225M | 205M | 143M | -54.9M | -146M | 188M | 256M | 336M |
| Net Income | 59.4M | 94.2M | 160M | 139M | 96.5M | -90.3M | -190M | 31.5M | 159M | 268M |
| EPS | 0.97 | 1.54 | 1.07 | 0.93 | 0.49 | -0.45 | -0.96 | 0.16 | 0.81 | 1.33 |
| Balance Sheet | ||||||||||
| Total Assets | 743M | 854M | 1.18B | 2.37B | 2.83B | 3.16B | 3.03B | 3.16B | 3.53B | 3.71B |
| Total Liabilities | 531M | 360M | 484M | 536M | 918M | 1.35B | 1.40B | 1.52B | 1.78B | 1.87B |
| Shareholders' Equity | 212M | 494M | 696M | 1.83B | 1.91B | 1.81B | 1.63B | 1.63B | 1.75B | 1.84B |
| Cash & Short-term Investments | 65.9M | 55.2M | 151M | 1.10B | 878M | 785M | 569M | 555M | 650M | 526M |
| Total Debt | 105M | 105M | 237M | 316M | 601M | 1.04B | 1.12B | 895M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 64.8M | 63.4M | 5.25M | 106M | 94.0M | -85.9M | -87.1M | 107M | 86.0M | - |
| Capital Expenditure | 55.7M | 40.2M | 53.6M | 189M | 372M | 399M | 191M | 94.0M | 83.6M | 73.4M |
| Free Cash Flow | 9.09M | 23.2M | -48.3M | -83.0M | -278M | -485M | -278M | 12.7M | 2.40M | -22.9M |
| Ratios | ||||||||||
| ROE | 28.0% | 19.0% | 22.9% | 7.6% | 5.0% | -5.0% | -11.7% | 1.9% | 9.1% | 14.6% |
| ROA | 8.0% | 11.0% | 13.5% | 5.9% | 3.4% | -2.9% | -6.3% | 1.0% | 4.5% | 7.2% |
| Net Profit Margin | 9.6% | 10.6% | 13.4% | 11.4% | 7.5% | -6.9% | -15.1% | 2.2% | 10.3% | 22.1% |
| Debt to Equity | 0.50x | 0.21x | 0.34x | 0.17x | 0.31x | 0.57x | 0.69x | 0.55x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shandong Kexing Bioproducts Co. Ltd. A dividends
- Dividend yield
- 1.83%
- Forward dividend
- 0.25 CNY
- Payout ratio
- 36.0%
- Ex-dividend date
- Jun 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 57.4M | 0.29 | 36.0% |
| 2024 | CNY 43.6M | 0.22 | 138.6% |
| 2023 | CNY 45.4M | 0.23 | - |
| 2022 | CNY 19.9M | 0.10 | - |
| 2021 | CNY 15.9M | 0.08 | 16.5% |
| 2020 | CNY 10.9M | 0.07 | 7.8% |
| 2019 | CNY 7.01M | 0.05 | 4.4% |
| 2018 | 9.69M | 0.16 | 10.3% |
| 2017 | 48.3M | 0.79 | 81.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shandong Kexing Bioproducts Co. Ltd. A
- Insiders 52.50%
- Institutions 4.49%
- Public & others 43.02%
- Shares outstanding 202M
- Free float 100M
Shandong Kexing Bioproducts Co. Ltd. A company profile
- Company name
- Shandong Kexing Bioproducts Co. Ltd. A
- Ticker
- 688136.SHG
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,048
- Fiscal year end
- December
- Address
- No. 2666 Chuangye Road, Jinan, China, 250200
- Phone
- 86 531 5576 3609
- Website
- kexing.com
About Shandong Kexing Bioproducts Co. Ltd. A
Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields. It also develops GB05, a human interferon a1b inhalation solution that is in Phase III clinical trial; GB-K02, a human granulocyte colony-stimulating factor injection in Phase III clinical trial; GB08, a growth hormone that has completed Phase I clinical trial; GB10 for fundus diseases; GB12 for atopic dermatitis; GB18 for cancer cachexia; GB23 for solid tumors; GB24 for inflammatory bowel diseases; and GB25, a tri-specific antibody for colorectal cancer. In addition, the company's products include drugs, such as human erythropoietin, human interferon a1b and human granulocyte colony-stimulating factor injections, albumin-bound paclitaxel, infliximab injection, combined clostridium butyricum, apaltamethasone tablets, infliximab for injectio, ahrasin (adalimumab injection), liraglutide injection, smegglutide injection, boyoubi and bologna denosumab injection, nolantai, sevelam carbonate tablets, abersipu, sitagliptin phosphate tablets, propofol emulsion injection, teriparatide injection, tamsulosin hydrochloride extended-release capsules, oseltamivir phosphate dry suspension, and bifidobacterium powder/capsule. Kexing Biopharm Co., Ltd. was founded in 1997 and is based in Jinan, China.
Shandong Kexing Bioproducts Co. Ltd. A management
10- Mr. Yanqing ZhaoCEO, GM & Director · born 1982
- Ms. Xiaoqin WangCFO, Secretary to the Board & Director · born 1977
- Ms. Hongjie MaDeputy GM & GM of Technology Center · born 1971
- Ms. Ning CuiDeputy GM & Director · born 1977
- Mr. Suofu QinDeputy General Manager · born 1964
- Mr. Ke ShaoDeputy General Manager · born 1971
- Shu Ling WangAccounting Supervisor
- Mr. Fang Fang TianHead of the scientific research management center of the pharmaceutical research institute · born 1985
- Mr. Hui Ming LiDeputy General Manager of the New Drug Research Center · born 1970
- Ms. Wei ShangSenior Manager of cell biology - New Drug Research Center · born 1986